Literature DB >> 8872418

Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia.

A Wallin1, K Blennow, L E Rosengren.   

Abstract

Glial fibrillary acidic protein (GFAP) is the structural protein of the astroglial intermediate filament that forms the morphological basis of astrogliosis. In the present study, GFAP concentrations in cerebrospinal fluid were measured in patients with various dementia diseases. A significant correlation between GFAP and age was found both in the total dementia group and in the controls. Covariance analysis with GFAP as dependent variable and age and albumin ratio as covariates followed by multiple group comparisons showed that, with regard to GFAP levels, the controls (n = 39) differed significantly from the patients with vascular dementia (n = 20; p < 0.05), senile dementia of the Alzheimer type (n = 29; p < 0.05), and 'pure' Alzheimer's disease (n = 8; p < 0.05), but not from those with frontal lobe dementia (n = 5).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872418     DOI: 10.1159/000106891

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  15 in total

1.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

Authors:  M M Edwards; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

2.  Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations.

Authors:  Eduardo M Castaño; Chera L Maarouf; Terence Wu; Maria Celeste Leal; Charisse M Whiteside; Lih-Fen Lue; Tyler A Kokjohn; Marwan N Sabbagh; Thomas G Beach; Alex E Roher
Journal:  Neurochem Int       Date:  2012-12-08       Impact factor: 3.921

Review 3.  Biomarkers in translational research of Alzheimer's disease.

Authors:  Rawan Tarawneh; David M Holtzman
Journal:  Neuropharmacology       Date:  2010-04-13       Impact factor: 5.250

4.  Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants.

Authors:  R K Lee; S Knapp; R J Wurtman
Journal:  J Neurosci       Date:  1999-02-01       Impact factor: 6.167

5.  Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status.

Authors:  Gülin Oz; Diane Hutter; Ivan Tkác; H Brent Clark; Myron D Gross; Hong Jiang; Lynn E Eberly; Khalaf O Bushara; Christopher M Gomez
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

Review 6.  Dysfunctions of neuronal and glial intermediate filaments in disease.

Authors:  Ronald K H Liem; Albee Messing
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

7.  Age-associated changes in synaptic lipid raft proteins revealed by two-dimensional fluorescence difference gel electrophoresis.

Authors:  Lei Jiang; Jianwen Fang; David S Moore; Natalia V Gogichaeva; Nadezhda A Galeva; Mary L Michaelis; Asma Zaidi
Journal:  Neurobiol Aging       Date:  2008-12-31       Impact factor: 4.673

8.  Glial and neuronal damage markers in patients with anorexia nervosa.

Authors:  Stefan Ehrlich; Roland Burghardt; Deike Weiss; Harriet Salbach-Andrae; Eugenia Maria Craciun; Klaus Goldhahn; Burghard F Klapp; Ulrike Lehmkuhl
Journal:  J Neural Transm (Vienna)       Date:  2008-03-04       Impact factor: 3.575

9.  The fourth element targeting hypothesis of Alzheimer's disease pathogenesis and pathophysiology.

Authors:  Rodrigo O Kuljiš
Journal:  Front Neurol       Date:  2010-11-23       Impact factor: 4.003

Review 10.  Reliability of S100B in predicting severity of central nervous system injury.

Authors:  Stephen M Bloomfield; James McKinney; Les Smith; Jonathan Brisman
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.